The EU-funded SME Instrument program MIMESIS, has demonstrated on a large scale the efficiency and excellence of ENYO Pharma’s drug discovery approach. The research program took place from November 2016 to October 2018.
This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.
Project MIMESIS achieved the following:
- Increase the number of ENYO’s drug discovery targets (not previously considered tractable to drug development) and preclinical small molecule assets
- Broaden ENYO’s therapeutic priorities to include both infectious and non-infectious diseases
- Demonstrate the value of ENYO’s library of small molecules that mimic the strategies used by viruses to regulate human cell biology
- Exploit successful identification of novel targets and chemistries for possible licensing relationships with the pharmaceutical industry
Success of the EU-funded MIMESIS programme has verified that ENYO’s approach can be considered a drug discovery engine delivering novel targets and chemistries as starting points for drug discovery. ENYO Pharma has identified and optimized three novel chemistries that potently inhibit Zika virus and RSV replication and also induce immunogenic cell death in treated tumor cells. The library has also been screened in phenotypic assays against Influenza virus, Human Rhinovirus and Tuberculosis although these programmes remain at an earlier stage.
All phenotypic screens carried out as part of the MIMESIS programme delivered promising hits (some with sub-uM potency and no cytotoxicity).
ENYO Pharma is open to discuss collaborations and partnerships to screen it’s “MIMESIS compound library” and/or further optimize and develop its existing preclinical hits and leads.